| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; and Huyabio. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Mily Elizabeth | EVP, Strategy & BD | Apr 01 | Option Exercise | 0.00 | 6,346 | 0 | 5,380 | Apr 02 01:14 PM | | Caforio Giovanni | Chairman and CEO | Mar 22 | Sale | 62.20 | 25,000 | 1,555,000 | 528,980 | Mar 24 04:41 PM | | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Mar 10 | Option Exercise | 0.00 | 5,404 | 0 | 19,811 | Mar 12 06:59 PM | | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Mar 10 | Option Exercise | 0.00 | 25,215 | 0 | 41,325 | Mar 12 06:59 PM | | Caforio Giovanni | Chairman and CEO | Mar 10 | Option Exercise | 0.00 | 200,709 | 0 | 603,187 | Mar 12 06:59 PM | | Eid Joseph | SVP,Head Glob. Medical Affairs | Mar 10 | Option Exercise | 0.00 | 6,134 | 0 | 9,862 | Mar 12 06:58 PM | | Elkins David V | EVP, Chief Financial Officer | Mar 10 | Option Exercise | 0.00 | 8,025 | 0 | 91,211 | Mar 12 06:57 PM | | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Mar 10 | Option Exercise | 0.00 | 4,189 | 0 | 9,082 | Mar 12 06:56 PM | | LEUNG SANDRA | EVP, General Counsel | Mar 10 | Option Exercise | 0.00 | 50,373 | 0 | 383,564 | Mar 12 06:52 PM | | Santiago Karen Murphy | SVP & Controller | Mar 10 | Option Exercise | 0.00 | 7,483 | 0 | 14,717 | Mar 12 06:50 PM | | Powell Ann | EVP, Chief Human Resources | Mar 10 | Option Exercise | 0.00 | 29,835 | 0 | 76,125 | Mar 12 06:51 PM | | von Autenried Paul | EVP, Chief Information Officer | Mar 10 | Option Exercise | 0.00 | 20,302 | 0 | 143,800 | Mar 12 06:50 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Mar 10 | Option Exercise | 0.00 | 7,423 | 0 | 79,051 | Mar 12 06:50 PM | | Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | Mar 10 | Option Exercise | 0.00 | 31,575 | 0 | 53,018 | Mar 12 06:50 PM | | Elkins David V | EVP, Chief Financial Officer | Mar 01 | Option Exercise | 0.00 | 24,579 | 0 | 91,759 | Mar 03 05:27 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Mar 01 | Option Exercise | 0.00 | 23,349 | 0 | 80,572 | Mar 03 05:26 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Feb 04 | Option Exercise | 0.00 | 3,592 | 0 | 58,409 | Feb 08 07:28 PM | | Elkins David V | EVP, Chief Financial Officer | Dec 31 | Option Exercise | 0.00 | 20,624 | 0 | 79,111 | Jan 05 08:13 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Dec 31 | Option Exercise | 0.00 | 25,866 | 0 | 68,074 | Jan 05 08:14 PM | | AHMED NADIM | EVP and President, Hematology | Dec 31 | Option Exercise | 0.00 | 14,946 | 0 | 46,549 | Jan 05 08:13 PM | | Elkins David V | EVP, Chief Financial Officer | Dec 02 | Option Exercise | 0.00 | 8,792 | 0 | 63,574 | Dec 03 08:24 PM | | AHMED NADIM | EVP and President, Hematology | Dec 02 | Option Exercise | 0.00 | 6,594 | 0 | 34,983 | Dec 03 08:24 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Dec 02 | Option Exercise | 0.00 | 8,792 | 0 | 46,714 | Dec 03 08:24 PM | | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Dec 02 | Option Exercise | 0.00 | 2,637 | 0 | 23,670 | Dec 03 08:23 PM | | Eid Joseph | SVP,Head Glob. Medical Affairs | Dec 01 | Option Exercise | 0.00 | 2,825 | 0 | 5,359 | Dec 03 05:15 PM | | von Autenried Paul | EVP, Chief Information Officer | Nov 25 | Sale | 63.50 | 3 | 190 | 126,698 | Nov 30 05:52 PM | | von Autenried Paul | EVP, Chief Information Officer | Nov 24 | Sale | 62.75 | 20,000 | 1,255,000 | 126,701 | Nov 25 04:31 PM | | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | Nov 24 | Sale | 63.39 | 900 | 57,051 | 15,186 | Nov 25 04:32 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Nov 23 | Sale | 61.34 | 13,421 | 823,244 | 37,922 | Nov 25 04:32 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Nov 19 | Option Exercise | 49.28 | 52,213 | 2,572,887 | 98,355 | Nov 23 05:40 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Nov 19 | Sale | 61.30 | 57,591 | 3,530,269 | 46,142 | Nov 23 05:40 PM | | AHMED NADIM | EVP and President, Hematology | Oct 30 | Option Exercise | 0.00 | 4,650 | 0 | 30,680 | Nov 03 04:28 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | Oct 30 | Option Exercise | 0.00 | 5,804 | 0 | 59,580 | Nov 03 04:27 PM | | Santiago Karen Murphy | SVP & Controller | Sep 01 | Option Exercise | 0.00 | 642 | 0 | 8,390 | Sep 02 04:33 PM | | Caforio Giovanni | Chairman and CEO | Aug 31 | Sale | 62.70 | 39,840 | 2,497,968 | 445,584 | Sep 02 04:34 PM | | Eid Joseph | SVP,Head Glob. Medical Affairs | Aug 17 | Sale | 64.00 | 5,327 | 340,928 | 2,534 | Aug 19 06:15 PM | | LEUNG SANDRA | EVP, General Counsel | Aug 13 | Sale | 63.24 | 141,420 | 8,943,401 | 432,744 | Aug 17 04:55 PM | | Elkins David V | EVP, Chief Financial Officer | Aug 01 | Option Exercise | 0.00 | 46,402 | 0 | 80,698 | Aug 04 04:43 PM | | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Jul 01 | Option Exercise | 0.00 | 9,356 | 0 | 9,356 | Jul 02 04:56 PM | | Santiago Karen Murphy | SVP & Controller | Jul 01 | Option Exercise | 0.00 | 1,069 | 0 | 8,115 | Jul 02 04:54 PM | | Paliwal Dinesh C | Director | Jun 15 | Buy | 54.50 | 9,174 | 499,983 | 22,109 | Jun 16 05:15 PM | | Haller Julia A | Director | Jun 14 | Option Exercise | 0.00 | 558 | 0 | 6,819 | Jun 16 05:15 PM | | BONNEY MICHAEL W | Director | Jun 14 | Option Exercise | 0.00 | 558 | 0 | 8,650 | Jun 16 05:16 PM | | Haller Julia A | Director | Jun 13 | Option Exercise | 0.00 | 903 | 0 | 6,261 | Jun 16 05:15 PM | | BONNEY MICHAEL W | Director | Jun 13 | Option Exercise | 0.00 | 903 | 0 | 8,092 | Jun 16 05:16 PM | | Eid Joseph | SVP,Head Glob. Medical Affairs | Jun 03 | Option Exercise | 0.00 | 2,154 | 0 | 8,599 | Jun 09 07:15 PM | | Haller Julia A | Director | Jun 03 | Option Exercise | 0.00 | 2,949 | 0 | 5,358 | Jun 05 04:39 PM | | BONNEY MICHAEL W | Director | Jun 03 | Option Exercise | 0.00 | 2,949 | 0 | 7,189 | Jun 05 04:40 PM | | Dubow Adam | SVP,ChiefCompliance&EthicsOff. | May 22 | Sale | 61.01 | 3,200 | 195,232 | 16,086 | May 26 05:17 PM | | Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | May 19 | Sale | 62.68 | 25,000 | 1,567,000 | 26,777 | May 21 05:22 PM | | VESSEY RUPERT | EVP, Research & Early Dev. | May 01 | Option Exercise | 0.00 | 10,707 | 0 | 59,050 | May 05 04:49 PM | | AHMED NADIM | EVP and President, Hematology | May 01 | Option Exercise | 0.00 | 2,908 | 0 | 27,463 | May 05 04:49 PM |
|
